{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:54:55Z","timestamp":1792713295212,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,5,5]],"date-time":"2012-05-05T00:00:00Z","timestamp":1336176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1136\/annrheumdis-2011-201244","type":"journal-article","created":{"date-parts":[[2012,5,20]],"date-time":"2012-05-20T11:29:12Z","timestamp":1337513352000},"page":"517-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":487,"title":["Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease"],"prefix":"10.1016","volume":"72","author":[{"given":"Gerd R","family":"Burmester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J","family":"McIlraith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P M","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2011-201244_bib1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1136\/annrheumdis-2011-201244_bib2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.semarthrit.2004.11.006","article-title":"The benefit\/risk profile of TNF-blocking agents: findings of a consensus panel.","volume":"34","author":"Hochberg","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201244_bib3","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3899\/jrheum.100995","article-title":"Does anti-tumor necrosis factor-\u03b1 therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of long-term data","volume":"38","author":"Keystone","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2011-201244_bib4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201244_bib5","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.","volume":"64","author":"Dommasch","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/annrheumdis-2011-201244_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2011-201244_bib7","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.281.9.824","article-title":"Postmarketing surveillance and adverse drug reactions: current perspectives and future needs.","volume":"281","author":"Brewer","year":"1999","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2011-201244_bib8","series-title":"International Agency for Research on Cancer","article-title":"Statistical methods in cancer research: vol II \u2013 the design and analysis of cohort studies","author":"Breslow","year":"1987"},{"key":"10.1136\/annrheumdis-2011-201244_bib9","unstructured":"Scotto J, Fears TR, Fraumeni JF, Jr,. Incidence of nonmelanoma skin cancer in the United States. Bethesda, MD: US Dept of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 1983. NIH publication 83\u20132433."},{"key":"10.1136\/annrheumdis-2011-201244_bib10","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1136\/ard.2008.102103","article-title":"Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases.","volume":"68","author":"Burmester","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"10.1136\/annrheumdis-2011-201244_bib11","first-page":"265","article-title":"Impact of screening for latent TB prior to initiating anti-TNF therapy in North America and Europe","volume":"64","author":"Perez","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201244_bib12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201244_bib13","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ibd.20956","article-title":"Adalimumab safety in global clinical trials of patients with Crohn's disease.","volume":"15","author":"Colombel","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1136\/annrheumdis-2011-201244_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/11587890-000000000-00000","article-title":"The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials.","volume":"12","author":"Leonardi","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1136\/annrheumdis-2011-201244_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semarthrit.2010.03.003","article-title":"A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.","volume":"40","author":"Curtis","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201244_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/BOR.0b013e3282f4b392","article-title":"The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis.","volume":"20","author":"Askling","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/annrheumdis-2011-201244_bib17","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/ard.2006.067660","article-title":"All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.","volume":"66","author":"Carmona","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201244_bib18","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents.","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201244_bib19","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201244_bib20","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis.","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201244_bib21","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.23913","article-title":"Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.","volume":"59","author":"Lacaille","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201244_bib22","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1136\/annrheumdis-2011-201244_bib23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1136\/annrheumdis-2011-201244_bib24","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2011-201244_bib25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201244_bib26","author":"FDA Drug Safety Communication"},{"key":"10.1136\/annrheumdis-2011-201244_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.","volume":"20","author":"Ko","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"10.1136\/annrheumdis-2011-201244_bib28","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/art.22811","article-title":"Development of psoriasis after B cell depletion with rituximab.","volume":"56","author":"Dass","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201244_bib29","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1365-2133.2008.08470.x","article-title":"New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra.","volume":"158","author":"Gonz\u00e1lez-L\u00f3pez","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1136\/annrheumdis-2011-201244_bib30","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systemic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201244_bib31","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/art.27402","article-title":"Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis.","volume":"62","author":"Hellgren","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201244_bib32","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201244_bib33","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2011-201244_bib34","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201244_bib35","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/jnci\/90.17.1278","article-title":"Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study.","volume":"90","author":"Stern","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/annrheumdis-2011-201244_bib36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1136\/annrheumdis-2011-201244_bib37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.","volume":"120","author":"Paul","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1136\/annrheumdis-2011-201244_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clindermatol.2008.09.001","article-title":"Melanoma epidemiology and trends.","volume":"27","author":"Garbe","year":"2009","journal-title":"Clin Dermatol"},{"key":"10.1136\/annrheumdis-2011-201244_bib39","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation.","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"issue":"Suppl 3","key":"10.1136\/annrheumdis-2011-201244_bib40","first-page":"423","article-title":"Anti-TNF therapy and risk of skin cancer, data from the Swedish ARTIS registry 1998\u20132006 (EULAR abstract FRI0201)","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201244_bib41","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201244_bib42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis.","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2011-201244_bib43","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201244_bib44","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrrheum.2009.219","article-title":"Vascular effects of biologic agents in RA and spondyloarthropathies.","volume":"5","author":"Szekanecz","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/annrheumdis-2011-201244_bib45","first-page":"696","article-title":"Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes.","volume":"34","author":"Caplan","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2011-201244_bib46","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2011-201244_bib47","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724099527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724099527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2011-201244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:40:04Z","timestamp":1739504404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724099527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0003496724099527"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2011-201244","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2011-201244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}